ストックスクリーナーアプリを入手
1.12
8.94%
-0.11
アフターアワーズ：
1.20
0.08
+7.14%
前日終値:
$1.23
開ける：
$1.2
24時間の取引高:
2.01M
Relative Volume:
2.59
時価総額：
$3.70M
収益：
$9.81M
当期純損益:
$-26.16M
株価収益率:
-0.0289
EPS:
-38.77
ネットキャッシュフロー:
$-17.45M
1週間 パフォーマンス:
-51.93%
1か月 パフォーマンス:
-75.28%
6か月 パフォーマンス:
-88.52%
1年 パフォーマンス:
-88.42%
1日の値動き範囲:
$1.02
$1.24
1週間の範囲:
$1.01
$1.85
52週間の値動き範囲:
$1.01
$29.00
Reshape Lifesciences Inc Stock (RSLS) Company Profile
名前
Reshape Lifesciences Inc
セクター
電話
949-429-6680
住所
1001 CALLE AMANECER, SAN CLEMENTE
RSLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
1.12 | 3.70M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Reshape Lifesciences Inc (RSLS) 最新ニュース
“Technology Stocks to Watch: CSDX, LYT, SINT, TRNR, RSLS, CYCU, TRUG Market Momentum Building” - The Globe and Mail
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.02% - Investing.com
United States shares higher at close of trade; Dow Jones Industrial Average up 0.02% - Investing.com India
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
ReShape Lifesciences prices $6M public offering - MSN
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
ReShape Lifesciences Raises Fresh Capital: $6M Strategic Financing Deal Unveiled - StockTitan
Reshape Lifesciences Says Pricing Of Upsized $6.0 Million Public Offering -February 15, 2025 at 11:18 pm EST - Marketscreener.com
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering - Yahoo Finance
ReShape Lifesciences® Prices Public Offering of 2,575,107 Units at $2.33 Each - Nasdaq
RSLS stock touches 52-week low at $2.57 amid market challenges - Investing.com Nigeria
RSLS stock touches 52-week low at $2.57 amid market challenges By Investing.com - Investing.com South Africa
ReShape Lifesciences secures key diabetes treatment patent - MSN
Vagus Nerve Stimulators Market Witness Growth: Booming Demand, - openPR
Key Trend Revolutionizing the Bariatric Surgery Devices Market in 2025: Olympus Fully Launches Next-Level S... - WhaTech
Synthetic Biosensors Market: Trends, Applications & Growth - openPR
CPI, Powell Testimony and Other Can't Miss Items this Week - The Globe and Mail
Why Amazon Could Be the Best Big Tech Investment of Q1 - The Globe and Mail
AI and Automation reshape revenue management in the Life Sciences industry - ETHealthWorld
Emera Incorporated Announces Results of Series F First Preferred Share Conversion - The Globe and Mail
Accuray (ARAY) Stock Surges Amidst Market Activity - GuruFocus.com
ReShape Lifesciences receives international patent in Israel for its proprietary diabetes neuromodulation technology; shares rise - MSN
ReShape Lifesciences® Granted Key International Patent in - GlobeNewswire
Groundbreaking Diabetes Tech Patent Win: ReShape's Neural Solution Could Eliminate Daily Medications - StockTitan
The Biggest Beneficiaries of the $500 Billion Stargate Project Might Not Even Be AI Companies. Here Are 2 Other Stocks I'm Keeping a Close Eye On. - The Globe and Mail
Bariatric Surgery Market to Surpass USD 3.34 Billion by 2032, Growing at a CAGR of 7.85% - EIN News
Electroceutical Devices Market Projected To Witness Massive Growth, 2025-2032 | Medtronic plc, Abbott Laboratories - openPR
Bariatric Surgery Devices Market: Robust Growth, Key Players, and Future Trends - openPR
Oklo’s Fuel Partnership Strengthens Bullish Case for Stock - The Globe and Mail
RSLS Stock Touches 52-Week Low at $4.07 Amid Market Challenges By Investing.com - Investing.com South Africa
RSLS Stock Touches 52-Week Low at $4.07 Amid Market Challenges - Investing.com India
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LBRDA, OMIC, NEUE, RSLS on Behalf of Shareholders - Stockhouse Publishing
GitLab (GTLB): 3 Reasons We Love This Stock - The Globe and Mail
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – RSLS, TURN, RDW, NEUE - Morningstar
Agnico Eagle and O3 Mining Issues a Reminder to O3 Mining Shareholders to Tender their Shares to Agnico Eagle's All Cash Offer Expiring January 23, 2025 - The Globe and Mail
ReShape Lifesciences amends convertible note terms with investor By Investing.com - Investing.com Australia
ReShape Lifesciences amends convertible note terms with investor - MSN
Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket - The Globe and Mail
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade - The Globe and Mail
Warren Buffett "Secretly" Owns 3 Industry-Leading Artificial Intelligence (AI) Stocks - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GLXZ, R - GuruFocus.com
ReShape Lifesciences updates on merger with Vyome Therapeutics - TipRanks
ReShape and Vyome to merge in all-stock deal By Investing.com - Investing.com Australia
ReShape and Vyome to merge in all-stock deal - Investing.com
ReShape Lifesciences® Provides Update on Merger Agreement - GlobeNewswire
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys - Yahoo Finance
ReShape Lifesciences Merges with Vyome, Sells Core Medical Device Portfolio to Biorad - StockTitan
Obesity Treatment Market is Booming Worldwide | Pfizer, Nutrisystem, Roche, - openPR
Rising Burden of Neurological Disorders in Emerging Economies Fuels Demand for Vagus Nerve Stimulation Therapy - PharmiWeb.com
Vagus Nerve Stimulators Market Growth in Future Scope 2024-2031 - openPR
Reshape Lifesciences Inc (RSLS) 財務データ
収益
当期純利益
現金流量
EPS
1.16%
0.10%
大文字化:
|
ボリューム (24 時間):